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Background and Aims. This study investigated the proportion of CD patients in clinical remission with clinical depression, and
coping strategies in those with severe depressive disorders. Materials and Methods. One hundred consecutive CD patients in
clinical remission were screened for anxiety and depression by using Hospital Anxiety and Depression Scale and patients with
depressive symptoms were further investigated by means of Cognitive Behavioural Assessment 2.0 and Beck Depression Inventory
(BDI). Afterwards the coping strategies were assessed through the Brief-COPE questionnaire. Results. Twenty-one patients had
anxious symptoms and 16 had depressive symptoms with or without anxiety. Seven of these patients (43.8%) showed significant
depressive symptoms. Compared to patients without psychiatric disorders, these patients showed significant lower score in “positive
reframing” (𝑝: 0.017) and in “planning” (𝑝: 0.046) and higher score in “use of instrumental social support” (𝑝 < 0.001), in “denial”
scale (𝑝: 0.001), and in “use of emotional social support” (𝑝: 0.003). Conclusions. Depressed CD patients in clinical remission may
have dysfunctional coping strategies, meaning that they may not be able to implement functional strategies to manage at best stress
related with their disease.
1. Introduction
Crohn’s disease (CD) is an inflammatory chronic disease
that may affect any part of the gastrointestinal tract. Its
prevalence is increasing around the world, with an annual
incidence ranging from 12.7 to 20.2 per 100,000 person-
years, respectively, in Europe and North America, and a
prevalence ranging from 319 to 322 per 100,000 persons [1].
Crohn’s disease has a variable clinical evolution, characterized
by extraintestinal manifestations and intestinal and perianal
complications frequently requiring surgical treatment with
significant negative impact on quality of life.
A significant proportion of CDpatients shows psychiatric
comorbidity, in particular depressive and anxious disorders
[2, 3]. It has been estimated that the long-life prevalence of
the major depression and anxiety disorders can affect more
than 30% of patients in clinical remission and up to 60–80%
of patients with active CD [2, 4–7]. Furthermore, the role of
the depression on the severe impairment of quality of life [7,
8] and in reactivation of the CD [9–11] has been highlighted.
Another important psychosocial factor affecting quality
of life and disease reactivation in CD is coping style [12–14].
Coping style is commonly defined as someone’s preferredway
of dealing with stressful situations. Maladaptive coping is a
technique that may reduce symptoms while maintaining and
strengthening the disorder. This has been interpreted as an
emotional reaction against the pain in terms of dramatization
[15] or as a feeling of helplessness to deal with the stressor
and relying on others to resolve the stressful event or situation
and interpreted as a psychological factor more linked to the
emotional sphere, or social habits that can affect the patient’s
behaviour [16].
A link between depression and dysfunctional coping
strategies is well known [17, 18] and it has been reported
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in several conditions such as rheumatoid arthritis [19],
fibromyalgia [20, 21], chronic and arthritis pain [22, 23],
cancer [24], HIV patients [25], and patients in the chronic
phase after stroke [26], and women undergoing in vitro
fertilization [27]. However, their occurrence in CD remains
largely uninvestigated.
Therefore, we assessed the prevalence altered coping
strategies in a series of hospital-based out-patients with CD
in clinical remission with confirmed depressive disorder, in
order to identify potential areas of intervention.
2. Materials and Methods
2.1. Study Design. This prospective study included a series
of consecutive patients with endoscopic and histological
diagnosis of CD, defined according to the criteria of the
literature [28]. These patients were recruited between March
and September 2014, during an ambulatory visit at the IBD
unit of the Luigi SaccoUniversityHospital inMilan, a tertiary
referral centre for IBD care.
The eligible patients were first screened to identify
the presence of anxious/depressive symptoms (Step 1); then
patients with depressive symptoms were further investigated
to confirm and assess the severity of depression (Step 2).
Afterwards the coping strategies of these patients were
analysed (Step 3) and compared with those of CD patients
without psychiatric symptoms.
2.2. Patients. An unselected series of patients aged between
18 and 85 years with confirmed diagnosis of CD, in a status
of clinical remission, regularly followed up in our unit,
were considered eligible for this study. The patients were
excluded if they showed the following conditions: clinically
active disease (Crohn’s Disease Activity Index (CDAI) > 150),
diagnosis of psychiatric disorder preceding the diagnosis of
Crohn’s disease, pregnant patients, patients with history of
substance abuse, or significant comorbidity including the
diagnosis of neoplastic diseases.
All the patients included were informed about the nature
of the study and gave their consent to process their data. The
studywas approved by the Ethical Committee and the Review
Board of our Hospital.
2.3. Evaluation Steps. Eligible patients
underwent the following investigations.
Step 1. The presence of psychological distress, in particular
anxiety and/or depressive symptoms, was initially investi-
gated through the Hospital Anxiety and Depression Scale
(HADS). The scale is composed of 14 items, 7 for evaluat-
ing the anxious symptomatology and 7 for evaluating the
depressive symptomatology. Every item can show a score
ranging from 0 to 3, resulting in maximum 21 points for both
subscale “anxiety” and subscale “depression.” Scores equal to
or higher than 11 on each scale were considered indicative of
the presence of a disorder; scores from8 to 10were considered
indicative of a mild symptomatology, or borderline cases,
while scores from 0 to 7 were considered indicating a patient
without disorders. A meta-analysis of 2010 indicated the
values of sensibility and specificity of the HADS in order to
identify a Major Depressive Disorder: correspondingly 0.82
and 0.74, using as cut-off the score 8, and 0.56 and 0.92, using
as cut-off the score 11.The samemeta-analysis found values of
sensibility and specificity of 0.78 and 0.74 (with a cut-off set
at 8) in order to identify Generalized Anxiety Disorder [29].
Step 2. The patients with depression with or without anxiety,
namely, patients with HADS scores ≥ 8 in the subscale
“depression,” were investigated by means of the “ques-
tionnaire D” that represents the sheet 8 of the Cognitive
Behavioural Assessment (CBA) 2.0.This questionnaire D has
been used as further primary screening instrument.TheCBA
2.0 is a set of ten sheets investigating some primary psy-
chological constructs such as state anxiety, depression, fears,
obsessions, compulsions, and psychophysiological disorders
and tends to identify potential dysfunctional areas [30].
The items of each sheet are homogeneous for formal aspect
or historical derivation and probe a specific aspect of the
patient. The questionnaire D (sheet 8) assesses the depressive
symptoms through 24 dichotomous response items (yes/no),
among them there are critical items aiming at investigating
specifically depressive manifestations of particular clinical
interest. The scores higher than 95th percentile are deemed
significant. The questionnaire D has a high internal consis-
tency (Cronbach’s alpha = 0.87). The constant follow-up of
regulatory data and the particular attention paid in building
it make the CBA 2.0 one of the best “self-report” instruments
for the psychodiagnostic testing (Cronbach’s alpha between
0.74 and 0.85 in community and between 0.68 and 0.97 in
clinical environment) [31].
In patients that achieved scores higher than the 95th
percentile at this, the severity of depression was assessed
through the Beck Depression Inventory (BDI). BDI allows
investigating in a more detailed and deeper way the patients’
depressive symptoms and assesses their severity. The scale
is focused on 21 symptomatic areas and the patient is asked
about how they have been feeling in the last week. The
first 13 items represent the cognitive-affective subscale and
the following 13 the subscale of somatic and performance
symptoms. Each symptom changes according to four levels
(from zero to three) ranging in intensity. The scores allow
identifying five descriptions: (a) possible denial of depression,
pretending to be well (less than four points); (b) minimal
depression (5–9 points); (c) from mild to moderate depres-
sion (10–18 points); (d) from moderate to severe depression
(19–29 points); (e) severe depression (30–63 points). BDI has
an internal consistency between 0.79 and 0.90 depending
on the group of patients. Since a score beyond 40 is too
high even for a case of severe depression and suggests a
possible exaggeration of depression, patients with this score
were excluded [32].
Summarizing, Step 1 was to screen the anxiety and
depressive symptomatology; that does notmean a psychiatric
disorder, but only psychological distress. In the Step 2, the
patients with HADS score positive for depression were fur-
ther investigated to confirm and assess presence and severity
Gastroenterology Research and Practice 3
of depressive disorder (first the CBA-D test and second Beck
Depression Inventory), which scored the severity of cluster
symptoms usually used as diagnostic criteria (DSM).
Step 3. Finally, the coping strategies of the patients who
resulted positively after the questionnaire D of the CBA
2.0 and BDI were assessed through the Brief-COPE. The
patients’ coping style, or rather how they usually copewith the
stressing situations, was assessed through the Brief-COPE,
an abbreviated version of COPE created by the same author
[33]. The Brief-COPE comprises 28 items articulated in 14
scales composed of 2 items each. The items are assessed
according to a four-point scale from 1 (I usually do not do
this at all) to 4 (I usually do this a lot) and the patient is
asked to specify how many times it takes to implement the
proposed behaviour before a stressing situation. Compared
to the extended version (COPE), the Brief-COPE does not
comprise the less important items in the factor analysis
and/or those resulting in being less clear or hard to be
understood; furthermore a “self-blame” scale was added that
had resulted in being important from previous experiences.
The psychometric characteristics of the scales composing of
the Brief-COPE resulted in being satisfactory and also the
validity was provided with documentary evidence [33].
2.4. Statistical Analysis. The quantitative data were presented
as median and interquartile range (or IQR that is a measure
of statistical dispersion, being equal to the difference between
the upper and the lower quartiles, IQR = Q
75
− Q
25
). Com-
parison of scores between groups has been performed using
Mann-Whitney 𝑈 test for nonparametric data.
A value of𝑝 < 0.05was deemed as statistically significant.
3. Results
3.1. Patients’ Characteristics. Out of 100 patients initially
included in the study, 5 were excluded because of a diagnosis
psychiatric disorder before the diagnosis of CD. Demo-
graphic and clinical features of the 95 patients included in the
study are shown in Table 1.
3.2. Prevalence of Psychiatric Disorders. Thirty-seven patients
showed depressive or anxiety symptoms (HADS score on
one of both subscales ≥ 8). In particular, 21 patients (22.1%)
showed anxiety, 1 patient showed depressive symptoms, and
15 patients (15.79%) showed both conditions (Figure 1).
Six patients (6.3%) have been already treated for anxiety
or depressive symptoms: one patient with benzodiazepine,
1 patients with antidepressant SSRI, and 2 patients with a
combination of antidepressants (SSRI) and benzodiazepine
and 2 did not remember the treatment.Three of these patients
showed a residual symptomatology in the Hospital Anxiety
and Depression Scale (scores ≥ 8).
3.3. Severity of Depressive Symptoms. The 16 patients with
scores higher than or equal to eight in the subscale “depres-
sion”HADSwere investigated with the questionnaire D (QD)
of the Cognitive Behavioural Assessment 2.0 (sheet 8) and 7
Table 1: Demographic and clinical features of patients included in
the study.
Sex male, 𝑛 (%) 57 (60)
Age (years), mean (SD) 45 (14)
Age at diagnoses of CD (years), mean (SD) 28 (10)
Disease length (years), mean (SD) 20 (12)
Family history of IBD, 𝑛 (%) 16 (16.8)
Treatment, 𝑛 (%)
Immunosuppressive treatment 36 (37.9)
Treatment with anti-TNF-alpha 13 (13.7)
Mesalazine 24 (25.3)
No therapy (clinical observation) 22 (23)
Crohn’s disease’s localization 𝑛 (%)
Ileum 42 (44.2)
Colon 13 (13.7)
Ileocolonic 40 (42.1)
Isolated upper disease 3 (3.2)
Crohn’s disease’s behaviour 𝑛 (%)
Nonstricturing, nonpenetrating 28 (29.5)
Stricturing 45 (47.4)
Penetrating 22 (23.1)
History of perianal disease 10 (10.5)
Surgery, 𝑛 (%)
No surgery 35 (36.8)
Conservative surgery 10 (10.5)
Resective surgery 50 (52.6)
History of surgery for perianal disease 10 (10.5)
61.05%
22.11%
1.05%
15.79%
Anxiety
Depression
Anxiety and depression
Without psychological distress
Figure 1: Prevalence of anxiety or depression in the population
included in the study.
(43.8%) showed relevant depressive symptoms (scores > 95th
percentile in the QD); none of these patients has ever been
treated for depressive disorders.
These patients were submitted to the Beck Depression
Inventory that confirmed a severe depression (BDI score
between 30 and 40 points) in 2 patients, a moderate-severe
depression (BDI score between 19 and 29 points) in 4 patients,
and a mild-moderate depression (BDI score between 10 and
18 points) in 1 patient.
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Table 2: Coping strategies in CD patients with depression and those without psychiatric disorders expressed as median of the scores of each
item considered in the brief COPE.
Pts. with depression Pts. without psychiatric disorders
𝑝 value(𝑛 = 7) (𝑛 = 58)
Median (Q
25
–Q
75
) Median (Q
25
–Q
75
)
Positive reframing 4 (2.25–5.75) 6 (5–7) 0,017
Self-distraction 6 (4–6) 5 (4–7) 0,732
Venting 6 (4.25–7.75) 5 (4-5) 0,085
Use of instrumental support 7 (6–8) 5 (4–6) <0,001
Active coping 6 (6–8) 7 (5–8) 0,793
Denial 5 (4–6) 2 (2–4) 0,001
Religion 6 (3.5–6.75) 4 (2–6) 0,223
Humour 3 (2.25–4.75) 4 (3–5) 0,149
Behavioural disengagement 3 (2–4) 2 (2–4) 0,713
Use of emotional support 7 (6-7) 4 (3–5) 0,003
Substance use 2 (2-2) 2 (2-2) 0,345
Acceptance 7 (6.25–8) 8 (6–8) 0,891
Planning 5 (3.25–6) 6 (5–8) 0,046
Self-blame 3 (3–5) 4 (4-5) 0,286
3.4. Assessment of the Coping Strategies. The coping strategies
of patients with relevant depressive disorder and of those
without any psychiatric symptoms were assessed through the
Brief-COPE.
We found significant differences in coping styles adopted
by these groups. In particular, patients with depressive symp-
toms showed lower values of “positive reframing” (𝑝 = 0.017)
that refers to the items “I try to see it in a different light,
to make it seem more positive” and “I look for something
good in what is happening” and lower values in “planning”
(𝑝 = 0.046) that corresponds to the items “I try to come up
with a strategy about what to do” and “I think hard about
what steps to take.” Patients with depressive comorbidity
showed conversely higher points in “use of instrumental
social support” (𝑝 < 0.001) corresponding to the items “I talk
to someone to find out more about the situation” and “I try to
get advice from someone about what to do,” in the “denial”
scale (𝑝 = 0.001) that refers to the items “I say to myself this
isn’t real” and “I pretend that it hasn’t really happened,” and
in the one of “use of emotional social support” (𝑝 = 0.003)
that includes the items “I try to get emotional support from
friends or relatives” and “I get sympathy and understanding
from someone” (Table 2).
4. Discussion
Our study confirmed that psychiatric comorbidity is a fre-
quent condition in CD patients even in those in clinical
remission, confirming previous data [5] and that depressed
CD patients have altered coping strategies.
It is well known that CD is associated with higher
rates of anxiety and mood disturbances compared to the
general population and the European Crohn’s and Colitis
Organisation has underlined the importance to identify the
patients that need a psychiatric intervention, recommending
an interdisciplinary approach between gastroenterologist and
psychiatrist [34, 35]. In particular, we observed that 16.8%
of CD patients in clinical remission showed depressive
symptoms and nearly half of them (43.8%) corresponding
to the 7.3% of the overall study population had a definite
depression. However, considering that these data come from
a series of CD patients in clinical remission and that anxiety
and depression are far more frequent patients with active CD
[6, 36], our data likely underestimate the real prevalence of
psychiatric disorders in CD and therefore their impact on
coping strategies in CD patients.
Regarding the analysis of coping strategies in CD patients
we showed that patients with depression have significantly
lower levels of “positive reframing” and “planning” and
significantly higher levels of “denial” compared to CD
patients without psychiatric comorbidity. This means that
CD patients, before a stressing situation, tend to become
demoralized, are not able to implement functional strategies
to manage at best the stress, and, actually, prefer deny-
ing problems and avoiding them. This attitude reflects on
patients’ behaviour, resulting in a reduced compliance to
treatments and medical prescriptions, which is reported in
20% of patients with CD [37–40].
Patients with depression show significantly higher levels
of “use of emotional support” and “use of instrumental
support”; this means a deep dependence on the others,
requirement to find outside the resources to cope with
stressing situations in terms of both sympathy or comfort and
advices.Therefore the characteristics of passivity in their way
to cope with the stress are evident. This data is in keeping
with other preliminary studies that have shown a correlation
between passive coping and depression in patients with IBD
and CD in particular [41, 42].
Other studies highlighted the relation between coping
strategies and depression and suggested that a dysfunctional
coping style reduces the tolerance of physical symptoms and
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worsens patients’ quality of life and depressive disorders. On
the other hand, the typical manifestations of the depressive
disorder, like loss of interests, self-devaluation, and difficulty
in taking decisions, contribute to the patients use of passive
coping strategies such as avoidance, catastrophization, and
churning [15, 19, 21].
Crohn’s disease is characterized by alternate periods of
wellbeing and symptoms that can change look and social and
working functioning and usually cause significant recurring
stressors in patients. Considering that depression is frequent
in CD patients [2–4] most of them likely have a higher
probability to cope with stressing situations such as steroidal
and immunosuppressive therapies, hospitalizations, or sur-
gical operations. Therefore, interventions focused on coping
strategies should be considered as integrated treatment for
CD patients in order to improve their psychological wellbe-
ing. Accepting the disease as part of one’s life and trying to
get from the experience constructive aspects could result in
being essential to set new objectives and find motivational
resources to pursue them [43, 44]. On this regard, cognitive
behavioural therapy could be a useful resource in CDpatients
[45, 46]. Interventions of coping skills therapy have been
already shown to be useful in improving capacity of problem-
solving and patients’ psychological wellbeing [47]. However,
recent results investigating the effect of cognitive behavioural
therapy or other supportive therapies in patients with IBD
and depression suggested improvements of psychological
distress, global functioning, and quality of life [48, 49].
Besides these treatments, presently there are few data on the
efficacy of antidepressants and anxiolytics in CD, although
recent studies showed that antidepressants are associated
with a favourable outcome of the disease in IBD patients [50,
51]
.
Therefore, it is considered now important to approachCD
patients with depressive disorders intervening by means of a
pharmacologic and psychotherapeutical treatments in order
to improve compliance to the treatment, clinical features of
CD, and overall the patients’ quality of life.
Limitations of this study are the lack of data regarding
the possible risk factors for depression and the impact of the
socioeconomic level of patients on coping strategies (e.g., the
family income and the schooling level), and in turn the effect
of these on compliance to the treatment and overall quality
of life. These can be matter of future studies. Furthermore, in
order to answer the Brief-COPE questionnaire the patients
were requested to generalize their way to react to stressing
situations while the coping strategies can be partially changed
according to the event to cope with.
Finally, the major limitation in this study is that the
analysis was based on the comparison with only seven
patients with confirmed depression, a limited numerosity due
to strict selection of patients with confirmed depression. In
conclusion this study showed that CD patients in clinical
remission may have significant rate of anxiety and depressive
symptoms. The latter may be untreated and associated with
altered coping strategies. This potentially means that patients
may not be able to implement functional strategies tomanage
at best stress related with their disease. This confirms again
that CD patients may need an interdisciplinary approach
between gastroenterologist and psychiatrist.
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